Happy first Monday of 2026! The New Year is already off to an unusual start. Before I delve into too much detail, 2025 is now in our past, which I am thankful for, as it was not the best year. Of course, the past several years have been slightly challenging and frustrating. A few of the…
Breakthrough Again
Tweet I was asked what I thought of the MS in the media report. “Two new subtypes of MS found in ‘exciting’ breakthrough…Scientists have discovered two new subtypes of MS paving the way personalised treatments and better outcomes for patients” I choose not to comment on these papers becuase of the agro it causes, but…
New news from NICE..They are deluded to think this is anything new
Tweet There is new news that people with highly active MS have a new choice…they can have a biosimilar of Tysabri called Tyruko…whoopee-do. NICE recommend it because it is cheaper but in reality they are more or less the same, so why waste cash, but it is not really more choice, it is access to…
How I remember 2025 (without overdoing it)
This post would never end if I shared every photo from 2025. And, honestly, that wouldn’t tell the real story anyway. So, I gave myself a boundary: two photos per month. Not too little, not too much. Just enough to capture the moments that made me pause, laugh, adapt or feel especially grateful. This is…
Switching sideways or upwords..The only way is Up..Baby
Tweet This is what they say Is horizontal switching a valid strategy in the treatment of MS? “For people living with multiple sclerosis (MS), treatment changes are often necessary due to inadequate response, safety concerns, or personal preferences. These treatment switches can follow different strategies. One option is a “vertical switch,” where patients move to…
Myelin-targeting drug Lucid-MS inches closer to testing in patients
Quantum Biopharma has completed dosing in two toxicology studies requested by the U.S. Food and Drug Administration (FDA) that aim to support the launch of clinical studies of Lucid-MS, an experimental treatment for multiple sclerosis (MS) that’s designed to slow myelin loss. The 180-day toxicity and toxicokinetic studies were designed to evaluate any potential harmful…
Elizabeth Rash – MSAA’s January 2026 Artist of the Month
MSAA features the work of many talented artists affected by multiple sclerosis as part of our annual MSAA Art Showcase. Each month we share these artists’ inspiring stories and beautiful artwork with you as our Artist of the Month. This month, we celebrate Elizabeth Rash as January’s … Continue reading → Source: blog.mymsaa.org
Cladribine Real Life
Tweet Lucchini M, Borriello G, Haggiag S, Nicoletti CG, Fantozzi R, Buscarinu MC, Ferrazzano G, Cortese A, Marinelli F, Monteleone F, Centonze D, Conte A, Ferraro E, Gasperini C, Marfia GA, Pozzilli C, Salvetti M, Barbuti E, Bellucci G, Bianco A, Carlomagno V, Cruciani A, De Giglio L, Dionisi C, Ianniello A, Malimpensa L, Nasello…
FDA says Tolebrutinib is a Shania
Tweet Tolebrutinib inhibited clinical non-relapsing secondary progressive MS and thus became the first drug to do this. However whilst it showed a clinical slowing of disability, it failed to have benefit in other measures. More recently a trial was done in primary progressive MS and tolebrutininb failed to affect progression. The Federal Drug Administration has…
The Real Reason Slow Walkers Make Us So Angry
Hugh Grant has a famous rant about the unbearability of slow walkers. From road-raging speed demons to travelers rushing to board airplanes, most of us recognize the simmering irritation that comes from being slowed down by someone else. Impatience is still a socially acceptable emotion and we laugh at Hugh Grant’s outrage because we get…